(FILE 'HOME' ENTERED AT 12:14:58 ON 23 JUL 2001)

FILE 'EUROPATFULL, PCTFULL, USPATFULL, WPIDS' ENTERED AT 12:15:33 ON 23 JUL 2001

L1 724 S GLAXO WELLCOME/PA

E WELLCOME/PA

E GLAXO/PA

L2 50 S (GLAXO/PA OR WELLCOME/PA) (L) (LAMIVUDINE OR

(AMINO (6W) HYDROXYM

L3 50 DUP REM L2 (0 DUPLICATES REMOVED)

L4 19 S L3 NOT PY>=1998

L5 4 S L4(L) (HBV OR HEPATITIS)

L6 0 S L4(L) (ADEFOVIR OR PHOSPHONOMETHOXY(2W)ETHYL(2W)ADENINE)

L7 4 S L3(L) (ADEFOVIR OR PHOSPHONOMETHOXY(2W) ETHYL(2W) ADENINE)

L8 476 S ADEFOVIR OR PHOSPHONOMETHOXY(2W)ETHYL(2W)ADENINE OR PMEA

L9 9 S L8(L)L3

FILE 'INPADOC' ENTERED AT 12:41:57 ON 23 JUL 2001

L10 1 S WO9852949/PN

FILE 'EUROPATFULL, PCTFULL, USPATFULL, WPIDS' ENTERED AT 12:43:27 ON 23 JUL 2001

L11 201 S L8(L) (HBV OR HEPATITIS)

L12 44 S L11 NOT PY>=1998

L13 100 S ADEFOVIR(2A) DIPIVOXIL

L14 45 S L13(L) (HBV OR HEPATITIS)

L15 1 S L14 NOT PY>=1998

FILE 'USPATFULL' ENTERED AT 13:20:22 ON 23 JUL 2001

L16 12 S (ADEFOVIR OR PHOSPHONOMETHOXY(2W) ETHYL(2W) ADENINE OR

PMEA) (S)

L17 1 S L16 NOT PY>=1998

=> d ibib 1-4

L7 ANSWER 1 OF 4

ACCESSION NUMBER: 2000064427 PCTFULL EW 200044 ED 20001124

TITLE (ENGLISH): PHARMACEUTICAL FORMULATION

TITLE (FRENCH): FORMULATION PHARMACEUTIQUE

INVENTOR(S): KAWAMURA, Koho; MARUYAMA, Toshio; MISHIMA, Yasuhiro; SUGIBAYASHI, Nobuya

PATENT ASSIGNEE(S): GLAXO WELLCOME KABUSHIKI KAISHA

LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER KIND DATE
-----WO 2000064427 A2 20001102

DESIGNATED STATES:

AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT
TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ
UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES

FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA
GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 2000-JP2572 20000420 PRIORITY (ORIGINAL): GB 1999-9909154.8 19990422

L7 ANSWER 2 OF 4 PCTFULL COPYRIGHT 2001 MicroPatent

ACCESSION NUMBER: 2000016755 PCTFULL EW 200013 ED 20000428
TITLE (ENGLISH): ANTIVIRAL COMBINATIONS
TITLE (FRENCH): COMBINAISONS ANTIVIRALES

INVENTOR(S): BROWN, Nathaniel, A.; CONDREAY, Lynn, D.; GRAY,

Douglas, Fraser; RUBIN, Marc

PATENT ASSIGNEE(S): GLAXO GROUP LIMITED

LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER KIND DATE

WO 2000016755 A2 20000330

DESIGNATED STATES:

AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB

GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

APPLICATION INFO.: WO 1999-EP6886 19990917 PRIORITY (ORIGINAL): GB 1998-9820420.9 19980918

L7 ANSWER 3 OF 4 PCTFULL COPYRIGHT 2001 MicroPatent ACCESSION NUMBER: 1999064001 PCTFULL

TITLE (ENGLISH): METHODS AND COMPOSITIONS FOR INCREASING PENETRATION

OF

HIV

PROTEASE INHIBITORS

TITLE (FRENCH): METHODES ET COMPOSITIONS DESTINEES A ACCROITRE LA

PENETRATION DES

INHIBITEURS DE LA PROTEASE DU VIH

BROUWER, Kenneth, Russell; POLLI, Joseph, William

PATENT ASSIGNEE(S): GLAXO GROUP LIMITED

LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

INVENTOR(S):

NUMBER KIND DATE

WO 9964001 A2 19991216
DESIGNATED STATES: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK

EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ

MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD

ΤG

APPLICATION INFO.: WO 1999-EP3827 19990603 PRIORITY (ORIGINAL): GB 1998-9812189.0 19980605

L7 ANSWER 4 OF 4 PCTFULL COPYRIGHT 2001 MicroPatent

ACCESSION NUMBER: 1998052949 PCTFULL

TITLE (ENGLISH): CARBOCYCLIC NUCLEOSIDE HEMISULFATE AND ITS USE IN

TREATING VIRAL INFECTIONS

TITLE (FRENCH): HEMISULFATE DE NUCLEOSIDE CARBOCYCLIQUE ET SON

UTILISATION DANS

LE TRAITEMENT D'INFECTIONS VIRALES

INVENTOR(S): BRODIE, Alastair, Couper; JONES, Martin, Francis;

SEAGER, John, Frederick; WALLIS, Christopher, John

PATENT ASSIGNEE(S): GLAXO GROUP LIMITED

LANGUAGE OF PUBL.: English
LANGUAGE OF FILING: English
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER KIND DATE

WO 9852949 A1 19981126

DESIGNATED STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC

LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW GH

GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

BJ CF CG CI CM GA GN ML MR NE SN TD TG

APPLICATION INFO.: WO 1998-EP2835 19980514 PRIORITY (ORIGINAL): GB 1997-9709945.1 19970517

38

```
PCTFULL COPYRIGHT 2001 MicroPatent
     ANSWER 1 OF 1
ACCESSION NUMBER:
                         1997044063 PCTFULL
TITLE (ENGLISH):
                         DHA­ PHARMACEUTICAL AGENT CONJUGATES
TITLE (FRENCH):
                         CONJUGUES D'ACIDE <i>CIS </i>&shy;DOCOSAHEXANOIQUE
                         D'AGENTS
                         PHARMACEUTIQUES
INVENTOR(S):
                         BRADLEY, Matthews, O.; SHASHOUA, Victor, E.; WEBB,
                         Nigel, L.; SWINDELL, Charles, S.
                         NEUROMEDICA, INC.
PATENT ASSIGNEE(S):
LANGUAGE OF PUBL.:
                         English
LANGUAGE OF FILING:
                         English
DOCUMENT TYPE:
                         Patent
PATENT INFORMATION:
                         NUMBER
                                            KIND
                                                     DATE
                         WO 9744063
                                             A2 19971127
DESIGNATED STATES:
                         AU CA JP AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL
                         PT SE
APPLICATION INFO.:
                        WO 1997-US8867
                                                 19970522
PRIORITY (ORIGINAL):
                        US 1996-08/651312
                                                 19960522
DETD . . . Antirabies Serum; Antivenin (Latrodectus mactans);
     Antivenin (Micrurus
     Fulvius); Antivenin (Crotalidae) Polyvalent; KG Vaccine; Botulism
     Antitoxin; Cholera Vaccine;
     Diphtheria Antitoxin; Diphtheria Toxoid; DiplitheriaToxoid Adsorbed;
     Globulin, Immune; Hepatitis
    B Immune Globulin; Hepatitis B Virus Vaccine Inactivated;
     Influenza
     Virus Vaccine; Measles Virus
     Vaccine Live; Meningococcal Polysaccharide Vaccine Group A;
     Meningococcal Polysacchariide
     Vaccine Group C; Mumps Virus Vaccine.
     acarbose; aceclofenac; acemannan;
     acetoniepregenol; acety 1 -L-carn i tine;
     acetylcystelne, N-. acetylmethadol; acifran; acipimox; acitemate;
     acitretin; aclarubicin; aciatonium;
     napadisilatc; acomazide; acrivastinet; adafenoxate; adapalene;
     adatanserin; adecypenol; adefovir
       dipivoxil; adelmidrol; ademetionine; adinazolam; adiposin;
     adozelesin;
     adrafinil; alacepril;
     aladapcin; alaptide; affiendazole; albolabrin; aldecalmycin;
aldesleukin;
     alendronic acid; alentemol;
     alfacalcidol. alfuzosin; aiglucerase; aiiiidstine; alosetron; alpha
     idosone. alprostadil. altretailline;
```

altromycin.

L17 ANSWER 1 OF 1 USPATFULL

ACCESSION NUMBER: 97:38508 USPATFULL

TITLE: Phosphorous prodrugs and therapeutic delivery systems

using same

INVENTOR(S): Glazier, Arnold, Newton, MA, United States

PATENT ASSIGNEE(S): Drug Innovation & Design, Inc., Newton, MA, United

States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 5627165

US 5627165 19970506 US 1994-310972 19940923 (8)

APPLICATION INFO.: RELATED APPLN. INFO.:

Continuation-in-part of Ser. No. US 1991-714130, filed

on 11 Jun 1991, now abandoned which is a

continuation-in-part of Ser. No. US 1990-537332, filed

on 13 Jun 1990, now abandoned

DOCUMENT TYPE:

Utility

FILE SEGMENT:

Granted

PRIMARY EXAMINER:

Wilson, James O.

LEGAL REPRESENTATIVE:

Hamilton, Brook, Smith & Reynolds, P.C.

NUMBER OF CLAIMS:

38

EXEMPLARY CLAIM:

1,36

NUMBER OF DRAWINGS:

20 Drawing Figure(s); 9 Drawing Page(s)

LINE COUNT:

2020

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD The **PMEA** prodrug was tested for its ability to inhibit hepatitis B viral replication by an in vitro assay as

previously described by Korba. Chronically hepatitis B

producing human hepatocyte (2.2.15 cells) were grown to confluence in microtitre wells. Test compounds were added daily for a 9 day period. The culture medium was changed daily and stored for quantitation of

extracellular hepatitis B viral (HBV) DNA

on days 0, 3, 6, and 10. On day 10 the cells were lysed and the intracellular HBV episomal monomeric DNA and HBV

replicative intermediates (RI) were quantitated. Toxicity of test compounds was assayed by treating confluent monolayers of the

hepatocyte

with graded.

DETD

Antiviral Activity of **PMEA** Prodrug 7-a Viral Prodrug

PMEA

Prodrug

PMEA

Prodrug

Ourug

Prodrug

Assay EC50 EC50

CC50 CC50

CC50/-EC50

Potency

HIV 1 CPE

.32* >20 2.4 >20 7.5 >62.5

HSV1 CPE

.06 68.5

(630

DETD .

Antiviral Activity of PMEA Prodrug 7-b Viral Prodrug

PMEA

Prodrug

PMEA

Prodrug

Prodrug

Assay EC50 EC50

CC50 CC50

CC50/-EC50

Potency

HIV 1 CPE

.006*

>20 .85 >20 141 >33005

HSV1 CPE

.63 68.5

52.9. . . Plaque

,

L12 ANSWER 34 OF 44 USPATFULL

ACCESSION NUMBER: 97:71178 USPATFULL

TITLE:

Nucleotide analogs

INVENTOR(S):

Bischofberger, Norbert, San Carlos, CA, United States

Jones, Robert J., Millbrae, CA, United States Arimilli, Murty, Fremont, CA, United States Lin, Kuei-Ying, Fremont, CA, United States Louie, Michael, Burlingame, CA, United States McGee, Lawrence R., Pacifica, CA, United States Prisbe, Ernest J., Los Altos, CA, United States

PATENT ASSIGNEE(S):

Gilead Sciences, Inc., Foster City, CA, United States

(U.S. corporation)

NUMBER KIND DATE US 5656745 19970812

PATENT INFORMATION:

APPLICATION INFO.:

US 1993-123483

19930917 (8)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

Granted

PRIMARY EXAMINER: LEGAL REPRESENTATIVE: Wilson, James O.

NUMBER OF CLAIMS:

Muenchau, Daryl D.

EXEMPLARY CLAIM:

29

NUMBER OF DRAWINGS:

7 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

bis-ester to a corresponding mixed ester-phosphoroamidate compound. . . . --O--C#H(CH.sub.2 N.sub.3)--CH.sub.2 --B, ##STR20## where C#, R.sup.25 -R.sup.29, R.sup.31 and B have the meanings previously defined with the proviso that PMEA bis(4-nitrobenzyl ester) and PMEA bis(4-trifluoromethyl ester) are excluded and for structure XXIX, R.sup.29 and R.sup.25 are both O. Additional ester and nucleotide compounds are. DETD Exemplary bis esters include bis(pivaloyloxymethyl) PMEA (i.e. bis (pivaloyloxymethyl) -9-(2-phosphonylmethoxyethyl) adenine), bis (pivaloyloxymethyl) HPMPC, bis (pivaloyloxymethyl) D4AMPI, bis (pivaloyloxymethyl) D4TMPI, bis (N-ethylmorpholino) PMEA, bis (N-ethylmorpholino) HPMPC, bis (N-ethylmorpholino) PMPDAP, bis (N-ethylmorpholino) HPMPA, bis (N-ethylmorpholino) PMEG, bis(N-ethylmorpholino)D4AMPI, bis(N-ethylmorpholino)D4TMPI, bis(phenyl) PMEA, bis(phenyl) HPMPC, bis(phenyl) HPMPA, bis(phenyl) D4AMPI, bis(phenyl)D4TMPI, bis(t-butyl)PMEA, bis(t-butyl)D4AMPI, bis(t-butyl)D4TMPI, bis(t-butyl)HPMPC, bis(2-ethoxyphenyl)PMEA , bis(2-ethoxyphenyl) HPMPC,, bis(4-fluorophenyl) PMEA, bis (4-fluorophenyl) HPMPC, bis (3,5-dimethoxyphenyl) PMEA, bis(3,5-dimethoxyphenyl)HPMPC and the like. DETD The compounds of structural formula Id shown are in Table 6 (bis(glycyl benzyl ester) PMEA (compound Ex 4), bis(alanyl benzyl ester) PMEA (Ex 1), bis(phenylalanyl benzyl ester)PMEA (Ex 5), etc. Compounds Ex 1-Ex 12 were synthesized by the following procedure. PMEA (Z--B.dbd.--CH.sub.2 --O--CH.sub.2 --CH.sub.2 --B, where B is adenin-9-yl) (0.3 g; 1.1 mmol) and amino acid ester.multidot.HCl (2.2 mmol; Sigma) were. . . using freshly prepared triphenylphosphine (6.0 mmol) and DETD